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Abstract 
Gaucher disease (GD) is caused by pathogenic mutations in GBA1, the gene that 
encodes the lysosomal enzyme β-glucocerebrosidase. Despite the existence of a 
variety of specific treatments for GD, they cannot completely reverse bone 
complications. Many studies have evidenced the impairment in bone tissue of GD, and 
molecular mechanisms of bone density alterations in GD are being studied during the 
last years and different reports emphasized its efforts trying to unravel why and how 
bone tissue is affected. The cause of skeletal density affection in GD is a matter of 
debates between research groups. and there are two opposing hypotheses trying to 
explain reduced bone mineral density in GD: increased bone resorption versus 
impaired bone formation. In this review, we discuss the diverse mechanisms of bone 
alterations implicated in GD revealed until the present, along with a presentation of 
normal bone physiology and its regulation. With this information in mind, we discuss 
effectiveness of specific therapies, introduce possible adjunctive therapies and present 
a novel model for GD-associated bone density pathogenesis. Under the exposed 
evidence, we may conclude that both sides of the balance of remodelling process are 
                                                                 











altered. In GD the observed osteopenia/osteoporosis may be the result of contribution 
of both reduced bone formation and increased bone resorption 
 













Gaucher disease (GD) (OMIM ID: 230800) is an autosomal recessive lysosomal 
disorder, caused by pathogenic mutations in the GBA1, leading to a deficient activity of 
the lysosomal enzyme β-glucocerebrosidase (GCase) (Enzyme Commission 3.2.1.45). 
Deficiency of GCase results in the accumulation of glucosylceramide (GL-1) specially, 
but not limited, to macrophages, and its derivative glucosylsphingosine (Lyso-GL1). 
Different phenotypes (types I, II and III) and heterogeneity have been described, and 
signs and symptoms may include hepatosplenomegaly, haematological alterations , 
skeletal abnormalities and in some cases neurological affection [1].  
Skeletal complications in type I and also type III Gaucher patients are the most relevant 
in terms of morbidity and life quality. Moreover, bone is the most refractory tissue to 
the specific therapy, such as enzyme replacement therapy (ERT), used for Type I GD. 
The complete explanation of these problems has not completely elucidated until now. 
Molecular mechanisms of bone density alterations in GD are being studied during the 
last years and different reports emphasized its efforts trying to unravel why and how 
bone tissue is affected. Normal bone density implies a delicate balance of bone 
homeostasis where bone formation and bone resorption are mutually regulated. 
Moreover, there is a delicate interaction between bone and immune system where 
any pathology in one of these systems affects the other. It is well known for many 
years the involvement of immune system in GD associated with the existence of a 
chronic inflammatory status that may have a deleterious influence in bone matrix 
homeostasis [2]  
The cause of skeletal density affection in GD is a matter of debates between research 
groups. According to the mechanisms that participate in bone homeostasis: bone 
formation and resorption, there are two opposing hypotheses trying to explain 
reduced bone mineral density in GD. One hypothesis is the existence of increased bone 
resorption, while the other is an impaired bone formation. In this review, we discuss 
the diverse mechanisms of bone alterations implicated in GD revealed until the 
present, along with a presentation of normal bone physiology and its regulation. With 











possible adjunctive therapies and present a novel model for GD-associated bone 
density pathogenesis.  
 
2. Skeletal manifestations in Gaucher patients 
Bone complication in GD is characterized by the presence of Erlenmeyer flask 
deformity of the femur, atypical bone pain, osteopenia or osteoporosis, extremely 
painful bone crises, avascular necrosis and pathological fractures including vertebral 
collapse. Furthermore, osteopenia and osteoporosis occurs earlier and in severe 
manner in Gaucher patients as compared to healthy individuals and may cause many 
pathological fractures [3]. Painful episodes could be acute or chronic, predominantly in 
the pelvis and lower limbs. The presentation observed in some GD patients with mild 
fever, leukocytosis and a moderate inflammatory syndrome could be misdiagnosed 
with osteomyelitis [3]. 
Studies in untreated and treated Gaucher patients have shown a similar prevalence of 
bone lesions among groups, ranging from 80 to 94% of incidence [4]. In GD registries, 
the proportion of patients with any bone involvement has been estimated in more 
than 80%. Interestingly, almost all of the registered patients were on specific 
treatment. An Argentinian study with 32 patients on ERT revealed that although 
patients had achieved the therapeutic goals for splenomegaly and hepatomegaly, they 
presented a high prevalence of bone lesions (84%) where 70% of them were 
irreversible [5]. The most common bone lesions are medular infiltration and 
osteopenia [6]. Another research including 32 Gaucher patients, which most of them 
were on specific treatment, showed significant bone manifestations: 72% of subjects 
presented with radiological changes, 59% reported bone pain and 50% with diminished 
bone density [7]. A recent study has used the trabecular bone score to characterize 
bone micro-architecture and its macroscopic geometry, which revealed an altered 
score in all of the patients assayed [8], even in those who have normal bone mineral 
density assessed by densitometry. This result, suggests that disruption of bone 
trabecular architecture could be present even with normal bone density. 
The adipose tissue is a preserved component of the microenvironment of the bone 
marrow that stabilizes this structure. It has been described that both the quantity and 











marrow fat and bone [9]. When bone marrow fat in lumbar spine was evaluated in 
Gaucher patients, it has been observed that patients without treatment had a very 
poor content. However, after ERT treatment, fat fraction increased significantly 
already after one year [10, 11]. 
Despite the different methods to evaluate the bone status, there are scarce reports of 
bone histology from GD patients. In a report of bone biopsies from three patients, the 
heterogeneity of GD presentation is manifested. Two of these cases presented low 
bone turnover and resembles a decrease of bone formation, on the contrary, the third 
biopsy included showed signs of resorption with high number of osteoclasts, 
inflammatory infiltration and fibrosis [12]. The largest histological study undergone by 
Dr Zimran´s group from Israel recruited 26 femoral head biopsies, which most of them 
were from patients on specific therapy. In this study, osteonecrosis and osteoarthritis 
were a common finding, as well as infiltration with Gaucher cells. Remodelling lines 
and increased osteoid deposition were evident in most samples, which is evidence of 
varying stages of bone regeneration [13]. 
 
3. Bone homeostasis 
3.1  Bone anatomy and physiology  
The human skeleton is formed by cortical and trabecular bone. Cortical bone is 
compact and forms the outer envelope of skeleton, while the trabecular is porous and 
located in the interior of bone structure. During life, bone is in continuous remodeling 
process where the old bone is substituted by new one [14]. Trabecular bone houses 
the marrow cells in a microenvironment with soluble mediators including cytokines 
and growth factors that participate in the hematopoiesis process [15], indicating a 
close relation between bone, hematological and the immune system. 
The ossification process is performed directly by the action of osteoblasts that 
proliferate from mesenchymal stem cells (MSCs) in response to the cytokines insulin-
like growth factor-I (IGF-I) and transforming growth factor β (TGFβ). The differentiation 
of MSCs is mediated by the osteogenic cytokines bone morphogenetic protein (BMP) 
and the Wingless (Wnt) signaling. Wnt proteins are a family of secreted glycoproteins 
that bind to receptor complexes present at the plasma membrane including low-











Binding of Wnt proteins to these membrane receptors acts on the most upstream 
intracellular component of the Wnt/ β-catenin pathway, the Disheveled (Dvl) proteins. 
This interaction promotes the phosphorylation and inactivation of GSK3β, which 
inhibits β-catenin degradation. Consequently β-catenin translocates to the nucleus 
[16], stimulating the expression of osteogenic genes Runt-related transcription factor 2 
(Runx2) and Osterix (Osx) [17-19] (Fig. 1). 
One of the osteoblasts functions is the production of bone extracellular matrix that is 
formed in part by organic components as type I collagen, osteopontin, and osteocalcin, 
among others. Consequently mineralization of organic matrix takes place by deposition 
of inorganic material, mainly hydroxyapatite [20]. The osteoblasts that remain 
embedded in this bone matrix reach the final state of differentiation: the osteocytes. 
Osteocytes establish a proper communication by their dendritic processes to form a 
network and participate in the regulation of bone remodeling with osteoblast and 
osteoclast [21, 22] through the production of both sclerostin and the nuclear receptor 
κB activated receptor ligand (RANKL). Sclerostin acts as antagonist of Wnt signaling 
pathway and inhibits BMP signaling, and RANKL promotes osteoclast formation, that is 
the osteoclastogenesis process [23-25]. 
Osteoclasts belong to the monocyte/macrophage lineage of hematopoietic origin and 
are the exclusive cells implicated in bone resorption. The osteoclasts differentiation 
process involves two key factors: the macrophage colony stimulating factor (M-CSF), 
generated by osteoblasts; and RANKL, generated by osteoblasts and osteocytes [26]. In 
this process, M-CSF binds to its c-fms receptor promoting the survival and proliferation 
of these cells [27, 28], while RANKL binds to its membrane RANK receptor to induce 
the fusion and differentiation of the precursors towards a mature osteoclast [29]. Bone 
resorption starts with its attachment to the bone matrix to be removed, acidification 
of extracellular microenvironment that mobilizes the mineral phase and secretion of 
matrix metalloproteinases (MMPs) and cathepsin K [30] which degrades organic 
matrix. The physiological bone remodeling process is schematised in figure 2. 
 
3.2 MSCs differentiation into osteoblasts or adipocytes 
MSCs can differentiate into multiple cell types: adipocytes, osteoblasts, myoblasts or 











growth factors present in the microenvironment. Among these potential outcomes, 
differentiation towards adipocytes and osteoblasts has special significance in the 
preservation of bone homeostasis. 
It has been demonstrated that age-related bone loss is associated with the increase in 
differentiation of MSCs into adipocytes with the consequent decline of osteoblasts 
number [31, 32]. This is in concordance with in vitro evidence that showed that 
adipocyte formation mediators inhibit osteogenesis and vice versa [33, 34]. Several 
transcriptional regulators participate in osteogenesis, among them Runx2 is the most 
relevant and is expressed by the osteoblast at all stages of development [18, 35, 36]. 
After commitment, Osx regulates the expression of many osteoblast differentiation 
markers [37]. On the other hand, adipocyte differentiation involves the expression of 
peroxisome proliferator-activated receptor gamma (PPARγ) and members of the 
CCAAT/enhancer binding proteins (C/EBP) family of transcription factors [38], which 
are known to be the vital transcription factors in the regulation of adipogenesis [39].  
Moreover, transcription factors that regulate osteogenesis and adipogenesis are 
reciprocally controlled. In particular, Runx2 expression is inhibited by PPARγ thus 
impeding osteoblast differentiation [40, 41]. The regulation between these cell linages 
ensures the cross talk of intricate signaling pathways involving the parathyroid 
hormone (PTH), parathyroid hormone-related protein (PTHrP), TGFβ, BMPs, Wnt 
proteins [42, 43] and Sirtuin 1 (Sirt1) [44], among others. 
The Wnt pathway stimulates osteogenesis through the regulation of expression of 
transcription factors including Runx2, Osx, and Distal-Less Homeobox 5 (dlx5), along 
with the inhibition of expression of adipogenic transcription factors C/EBP and PPARγ 
blocking adipocyte differentiation [45]. 
At physiological conditions Sirt1 expression is increased during the process of 
osteoblast differentiation inducing the up-regulation and activity of Runx2 [46, 47]. 
Additionally, Sirt1 inhibits adipocyte differentiation via interaction with PPARγ to 
recruit nuclear receptor co-repressor to its target promoters with the consequent 
inhibition of the expression of PPARγ-target genes [48]. However, in aged bone 
marrow, accumulation of ROS has the ability to repress the expression and also the 











MSC into adipocyte [49]. Other function related with Sirt1 is the ability of maintaining 
skeleton homoeostasis in inflammatory conditions by inhibiting NF-κB signal [50]. 
All these evidences showed that during MSC differentiation, osteogenesis and 
adipogenesis are mutually regulated processes (Fig. 3), but an imbalance could lead to 
a pathological condition. 
 
3.3 Osteoimmunology 
Bone tissue and immune system are closely related in physiological and pathological 
conditions. Bone and immune cells came from the same microenvironment and 
interact between each other to execute osteoimmunological functions. Studies 
performed in mice, have revealed the importance of immune system in bone 
development and homeostasis under physiological conditions [51].  
Recent evidences indicate that osteoblast participate in the process of differentiation 
of B and T lymphocytes [52, 53]. IL-7 secreted by osteoblast contribute in this event 
and also is implicated in the maintenance of lymphoid progenitors in bone marrow, 
indicating the ability to regulate lymphoid lineages [54]. Furthermore, osteoblast-
derived Dickkopf-1 (DKK1) acts as inhibitor of Wnt pathway in order to favor 
hematopoietic reconstitution via inhibition of hematopoietic stem cells senescence 
and the stimulation of bone marrow endothelial cells to produce epidermal growth 
factor (EGF) [55].  
The overlapping between bone and immune cells is also evidenced by osteoclasts, 
bone cells that originate from the same precursor of macrophages and dendritic cells. 
As was mentioned, in physiological conditions, osteoclast formation occurs in the 
presence of both M-CSF and RANKL cytokines produced by osteoblasts and MSCs that 
induce osteoclast differentiation from precursor cells , stimulating its activity and 
survival [56-58]. The RANKL receptor (RANK) is expressed in osteoclasts  and its 
expression is induced by the action of M-CSF on osteoclasts’ precursors. The 
interaction between RANKL and RANK is inhibited by osteoprotegerin (OPG), that act 
as neutralizing decoy receptor that is secreted by osteoblasts and MSCs [59]. Other 
cytokines and growth factors could also induce osteoclast differentiation in an 
inflammatory pathological condition [56]. In this context, the function of RANKL can be 











expressed in the membrane of T lymphocytes (LIGHT), B lymphocyte activating factor 
(BAFF), insulin-like growth factor (IGF)-I and II, nerve growth factor, IL-6, IL-8 or TGF-β 
[56]. In the case that the stimuli of M-CSF is absent, osteoclast differentiation can be 
triggered by vascular endothelial growth factor, hepatocyte growth factor, placental 
growth factor and FLt-3 [56]. Remarkably, other factors such as IL-23, IL-17, IL-7 and IL-
1 are involved in osteoclastogenesis indirectly by inducing RANKL secretion from a 
target cell [60, 61]. 
Th17 lymphocytes, not only contribute to osteoclastogenesis through the production 
of IL-17 promoting local inflammation, but also by expressing RANKL [62, 63] that is 
able to regulate immune response [64, 65]. The described non canonical pathways 
have a key role when these cytokines and growth factors are present as occur in the 
context of pathological bone injury during inflammatory diseases. 
On the other hand, osteoblasts are bone cells specialized in bone matrix deposition 
and regulation of bone balance. In conjunction with MSCs, osteoblasts produce RANKL 
and OPG [55]. Osteoblast has also a role in hematopoiesis [66]. Another factor that has 
influence in bone immune system is sclerostin produced by osteocytes. It has been 
demonstrated in mice models that deficiency in sclerostin not only induced high bone 
mass, but also a reduction in mature B lymphocyte because of the reduction in the 
secretion of the chemokine CXCL12 in MSCs [67].  
We can conclude that there is a close interaction between the immune and the 
skeletal systems, emphasizing the importance of the study of the interaction between 
them during bone pathology caused by infectious and chronic inflammatory 
conditions.  
 
4. Molecular Mechanisms involved in skeletal GD 
4.1 GD and osteogenesis  
In this section, we summarized the molecular mechanisms involved in the reduction of 
bone formation associated to GD as revealed by research studies using animal models 
as well as in vitro cell line studies. 
There have been many efforts to develop murine models of GD, starting with a 
knockout of GBA1. This mice presented deficient GCase activity and substrate 











Other strategies were analyzed including the introduction of GD associated mutations 
in GBA1; chemical GCase inhibition with conduritol beta epoxide (CBE) and backcross 
between saposin C deficient mice and GCase V394L/V394L mice, but these models are 
suitable for the study of neuropathic GD [69-72].  
In 2010 the first murine model for the non-neuropathic Type I GD has been developed 
[73], which recapitulates visceral and bone manifestations through conditional 
deletion of GBA1 in hematopoietic and mesenchymal cells [73]. Mice of this model 
presented a low bone mineral density (BMD) showing a significant osteopenia and 
reduction in bone formation rate. Osteoblasts from these mice model showed an 
attenuated proliferation and differentiation due to reduced protein kinase C activity 
caused by the accumulated lipids glucosylceramide and Lyso-GL1. Mistry’s group had 
not detected an increment in osteoclasts formation that could contribute to the 
observed osteopenia in these murine model. Besides this mice model, two in vivo 
Gaucher models based in zebrafish were developed. One of these models used a 
morpholino-based gene knockdown for Gba1 gene; while the other used a stable 
inheritable mutation generated by a forward genetic approach. Notably, both models 
lead to a truncated Gba1 protein and demonstrated a marked decrease in bone 
mineralization through the downregulation of canonical Wnt pathway and an increase 
in oxidative stress [74]. 
In the last decade, in vitro studies have been carried out using human MSCs from 
Gaucher patients as well as new cellular models originated by dedifferentiation of 
Gaucher patients’ fibroblasts into induced pluripotent stem cells (iPSCs) or MSCs [75-
79]. Using this approach, it was possible to analyze bone matrix formation in vitro by 
differentiating osteoblasts from MSCs in the appropriate culture media. It was 
observed that osteoblasts derived from Gaucher MSCs deposited less mineral matrix 
as well as type I collagen and also showed a decreased alkaline phosphatase activity 
[80-82].  
Bone matrix formation activity could be affected by a reduced proliferation of MSCs or 
its increased cell death. Impairment in proliferation is confirmed in Gaucher patients’ 
MSCs and in in vitro MSCs treated with CBE [75, 80], as well as in in vitro model of 
Gaucher MSCs derived from patients’ iPSC  [81, 82], showing an increased cell number 











Stromal cells cultures from mouse model of GD were also analyzed and showed a 
decrease proliferation evidenced by a MMT assay [56], however in Gaucher zebrafish 
model no global differences were observed in proliferation and apoptosis [74]. No 
changes or predisposition to cell death was observed [82] . 
Another explanation of a reduced bone matrix production could rely on an alteration 
in osteoblasts differentiation. The expression of osteogenic key genes such as Runx2 
and Osx are significantly reduced in Gaucher animal models as well as downstream 
genes such as alkaline phosphatase (Alp) and bone sialoprotein (Bsp) [73, 74]. In vitro 
studies in Gaucher osteoblasts derived from Gaucher MSCs corroborate these 
expression abnormalities where alkaline phosphatase (ALP), Type I Collagen (COLA1), 
osteocalcin and RUNX2 gene expression were lower than control cells [81, 82]. A 
described pathway associated to the regulation of these genes is the canonical Wnt 
signalling, whose activity is diminished in the Gaucher zebrafish model through 
demonstration of significantly reduced accumulation of β-catenin and increased levels 
of the negative regulators Gsk3β, Axin1 and Dkk-1 [74]. Besides, higher levels of Dkk-1 
were detected in supernatants of ex vivo Gaucher MSCs compared to control cells [75]. 
Furthermore, Wnt pathway signaling was studied in in vitro models of Gaucher 
osteoblast derived from Gaucher iPSCs, in which a decreased β-catenin levels as a 
consequence of increased activity of GSK3β was demonstrated [81]. Even more, Dvl 
proteins levels are reduced in GD fibroblasts and in human fetal osteoblasts treated 
with CBE [83]. Another player in this pathway is adiponectin, who was recently shown 
that facilitates osteogenesis through Wnt/β-catenin pathway [84]. Interestingly 
adiponectin is reduced in Gaucher patients, likely associated to their low grade chronic 
inflammation [85].  
Apart from Wnt pathway, a tight link between oxidative stress and reduced 
osteogenesis has been described [86], where molecular analysis and in vivo labelling in 
Gaucher models demonstrated the occurrence of an increased oxidative stress [74, 
87]. These results confirm an early dysfunction of the osteoblast population associated 
to reduced osteoblast differentiation and bone mineralization in GD. Furthermore, this 
global and early cellular alteration could be the result of an increase in oxidative stress.  
 











Most of the diseases that present bone loss with an inflammatory component evolve 
towards an alteration in the composition of adipose tissue of the bone marrow, where 
MSCs direct their differentiation towards adipocytes instead of osteoblasts [9, 88, 89]. 
In vitro model of osteoblasts differentiated from Gaucher patients’ MSCs has 
demonstrated that the accumulation of lactosylceramide and glucosylceramide lead to 
a reduction in calcium deposition giving, in part, an explanation of low bone density 
observed in GD [81]. Indeed, a recent study showed that the accumulation of 
glucosylceramide stimulates adipogenesis and inhibited osteogenesis by direct 
interaction with PPARγ through its A/B domain [79]. This evidence, could suggest that 
the accumulation of glucosylceramide in Gaucher MSCs would be able to induce 
adipogenesis. Our group have cultured Gaucher MSCs in adipogenic media, and 
observed a higher expression of PPARγ gene and lower levels of RUNX2 in Gaucher 
adipocytes than controls, suggesting that GD cells are preferentially induced to 
differentiate into adipocytes but accumulates lesser lipid droplets [82, 90], as also was 
observed by Campeau’s group [76]. These observations are compatible with bone 
marrow fat fraction analyzed in Gaucher patients with quantitative chemical shift 
imaging (QCSI) before treatment [10]. 
 
4.3 GD and Osteoclastogenesis  
Osteoclasts originate from the fusion of osteoclast precursors belonging to the 
monocyte/macrophage lineage, giving rise to multinucleated cells with tartrate-
resistant acid phosphatase (TRAP) activity capable to resorb bone. A high number of 
circulating osteoclast precursors have been reported in several bone diseases 
associated with bone loss [91] whose precursors are recruited from peripheral blood 
mononuclear cells (PBMCs) [92] followed by osteoclast formation through stimulation 
by RANKL and M-CSF [93].  
On one side, in vivo studies in Gaucher mice and zebrafish models have not shown 
differences in TRAP-positive osteoclast formation in comparison with controls animals, 
suggesting a normal osteoclast activity [73]. However, although histological studies 
from bone biopsies from GD patients are scarce, they can present evidence of bone 











chemical and Gaucher patient derived cell models unravelled alterations in 
osteoclastogenesis due to an increased osteoclast generation and bone resorption. 
The first in vitro chemical model based on the addition of CBE demonstrated that 
GCase deficiency in MSCs and PBMCs cause the secretion of proinflammatory 
cytokines as IL-8, IL-6, TNF-α and chemokines as MCP1 that induce osteoclastogenesis 
leading to formation of mature and active osteoclasts [80, 94]. Moreover, Mucci et al. 
have revealed the implication of TNF-α as well as T cells in osteoclastogenesis 
induction through RANKL. The presence of osteoclast was revealed by the expression 
of TRAP positive multinucleated cells that express vitronectin receptor and has the 
ability to secrete MMP-9 and resorb dentine [94, 95]. The knowledge that osteoblasts, 
osteocytes and MSCs can regulate bone resorption in vivo by the production of RANKL 
led to study their involvement in osteoclastogenesis. At the moment, it has been 
demonstrated that conditioned media from GCase deficient osteocytes and MSCs 
induce an increase differentiation of monocytes to osteoclasts  mediated by RANKL [75, 
96]; and the culture of Gaucher patients’ PBMCs either with M-CSF or M-CSF and 
RANKL induced higher number of active resorptive osteoclasts  than control PBMCs 
[97]. Moreover, a similar effect is observed when control PBMCs are cultured with 
glucosylceramide [98]. 
As it has been mentioned before, an inflammatory context could enhance 
osteoclastogenesis process through cytokines and GD is one of these disorders 
associated to an inflammatory context [2]. In this regard, the synergic effect of IL-1β 
with RANKL both secreted from Gaucher MSCs has been described [90]. Furthermore, 
the culture of Gaucher patients’ PBMCs has evidenced a secretion of other pro-
osteoclastogenic cytokines, including TNF-α and RANKL [97]. Finally, it is interesting to 
mention that a clinical correlation between in vitro osteoclast differentiation and bone 
mineral density has been revealed in GD1 patients [96, 98, 99]. Thus, these studies 
reinforce the idea there could also be an involvement of osteoclasts in bone density 
pathology of GD.  
 
5. Novel model of GD bone density pathogenesis 
Taking into account the reviewed evidence, we could be able to elaborate a novel 











BMD in physiological conditions is maintained by a delicate balance between matrix 
formation and resorption. The evidence based on both animal and in vitro models of 
GD highlight the reduced bone formation activity because of a disturbed proliferation 
and differentiation into osteoblasts progeny of MSCs, along as a reduced osteoblast 
bone formation function. On the other side, osteoclastogenesis and concurrent 
resorption activity by osteoclasts has been demonstrated in in vitro studies. Also, ex-
vivo studies using PBMCs from GD patients showed an increased number of osteoclast 
precursors and higher osteoclastogenesis  rate that correlate with densitometric 
studies as assessed in clinical setting of the same patients. Bone histological studies 
from GD patients are scarce, and reveal heterogeneity of processes, where both 
altered formation and resorption activity has been shown.  
Under the exposed evidence, we may conclude that both sides of the balance of 
remodelling process are altered. In GD the observed osteopenia/osteoporosis may be 
the result of contribution of both reduced bone formation and increased bone 
resorption. This knowledge could lead to the discovery of new therapeutic treatments 
that could be co-administered with the current therapy to improve patient’s response. 
 
6. Effect of therapies on skeletal manifestations in Gaucher patients 
 
In the present time, when there are several specific treatments for Gaucher patients  
available, bone affection is among the main concerns for physicians who treat these 
patients due to the variability of bone manifestations, which leads to a high morbidity 
rate and reduction of life quality [8]. Despite the complications, bone affection in 
Gaucher disease could be alleviated by specific Gaucher therapies and/or bone-
targeted ones.  
There are two approved approaches of Gaucher disease therapies: enzyme 
replacement (ERT) (imiglucerase, velaglucerase alfa, and taliglucerase alfa) and 
substrate reduction therapy (SRT) (miglustat and eliglustat). The effectiveness of these 
treatments depend on several factors: the age of diagnosis, the age when the patient 
initiate the therapy, the bone affection at the beginning of the therapy and the type of 











monitor the outcome of therapies, which shows a significant reduction levels at the 
beginning of the therapy but becomes less robust over time [101]. 
ERT has been demonstrated to be effective in reducing bone crisis, pain and infarction, 
all complications associated with bone marrow infiltration, whereas the improvement 
of BMD require a very long treatment span. Despite treatment, avascular 
osteonecrosis is irreversible. Gaucher disease may affect the achievement of optimal 
peak bone mass during adolescence, leading to higher prevalence of 
osteopenia/osteoporosis and fragility fractures in adulthood [102]. Improvement of 
BMD and growth rates in pediatric patients on ERT has been observed. Moreover, 
patients suffer fewer bone crises and occurrences of skeletal events, although ERT 
does not completely prevent them [3].  
Clinical trials results for SRT showed increases in BMD [103, 104]. Patients who were 
stable on ERT and were switched to SRT (miglustat) showed no change in bone pain 
[105]. Up to now, miglustat efficacy on bone symptoms remains poorly evaluated 
[106] and long term data for eliglustat is needed to fully evaluate its effects on bone 
disease. Another SRT drug, ibiglustat, is in clinical trials  [107].  
A new approach of specific treatment for GD is under clinical trial, and involves the use 
a chemical chaperone ambroxol, an FDA approved mucolytic drug. A pilot study of the 
use of Ambroxol showed improvement in hematological parameters in GD 1 patients  
[108], as well as bone manifestations in case reports  [109, 110]. A recent 
comprehensive study of bone involvement using MRI revealed a reduction of bone 
marrow score in patients on specific treatment, both ERT and SRT. However, bone 
complications such as bone infarcts, avascular necrosis  and bone crises are not 
completely eliminated [111], thus researchers introduce the idea of adjuvant 
therapies, targeted to correct a bone pathophysiological molecular mechanism. The 
first approach was the use of drugs typically used in osteoporotic patients, such as 
antiresorptive drugs or anabolic ones. Few studies on the effects of bisphosphonates 
have been reported in the literature (41, 42) but with heterogeneity of results and 
design of study [112]. The use of alendronate could be indicated as an adjuvant 
therapy in subjects with a marked reduction in bone mass  [113], however there was no 
benefit toward improvement of the focal lesions typically seen in patients with GD 











[115]. Another proposal is a combination therapy with romosozumab, a monoclonal 
antibody that binds sclerostin, leading to its dual effect of increasing bone formation 
and decreasing bone resorption [116].  
Therapeutic drugs directed to specific molecular target mechanisms have been proven 
in models of Gaucher disease. Activation of Wnt/β-catenin pathway by CHIR99021 was 
effective to induce bone formation in vitro [81]. Moreover, two anti-inflammatory 
drugs, anakinra and pentosan polysulfate were able to reduce osteoclastogenesis in 
Gaucher in vitro models [82, 117].  
The effectiveness of these drugs in in vitro models of Gaucher disease or in 
osteoporotic patients may represent a proof of concept for the design of clinical trials 
in order to extrapolate these results into clinic.  
 
Table I. Gaucher specific therapies. ERT: Enzyme Replacement Therapy; SRT: Sustrate 
Reduction Therapy 
Therapy Drug Comments 
ERT Imiglucerase FDA approved 
 Velaglucerase alfa  
 Taliglucerase alfa  
SRT Miglustat  
 Eliglustat  
 Ibiglustat In clinical trial 













Fig 1. Osteoblast maturation and differentiation mechanisms. Osteoblast precursors 
proliferate in response to IGF-I and TGFβ. IGF-I binds to the receptor tyrosine kinase 
IGFIR to activate MAPK pathway in osteoblasts and regulates RUNX2 transcription (1.). 
Additionally, TGFβ regulates RUNX2 transcription by phosphorylating SMAD2 and 
SMAD3. Osteoblast differentiation is mediated by BMP-2 and Wnt signaling (2.). 
Binding of bone morphogenetic protein (BMP) -2 to its receptor (BMPR) 
phosphorylating SMAD1 and SMAD5 proteins leads to the upregulation of RUNX2 and 
osterix (OSX), two transcription factors that control osteogenesis (3.). WNT proteins 
interact with the receptor frizzled and co-receptor LRP5 or LRP6 and then activate Dvl 
proteins promoting the phosphorylation of GSK3β to activate a signaling pathway that 
stabilizes cytoplasmic β-catenin (4.). Stabilized β-catenin is then translocated to the 
nucleus to induce genes that promote bone formation RUNX2, OSTERIX and BMP-2 
(5.). Activation of RUNX2 and/or OSX leads to increased expression of osteoblast-
specific genes, such as alkaline phosphatase and osteocalcin.  
 
Fig 2. Osteoblast and osteoclast differentiation and interaction. Osteoblasts (Ob) and 
adipocytes (Ad) derived from mesenchymal stem cells (MSCs). Adipocyte 
differentiation involves the expression of the transcription factors PPARγ and C/EBPβ 
(1.), and osteoblast differentiation involves the BMP and Wnt signaling that stimulate 
Runx2 and Osx expression (2.). Megakaryocyte and mature osteoblasts secrete TGF-β 
and IGF-1 that induced pre-osteoblasts differentiation (3.). IGF-1 and TGFβ also 
become incorporated into bone matrix and may be released later during resorption 
(9.). Differentiated osteoblasts produce organic components such as type I collagen, 
osteopontin and osteocalcin; and inorganic components as hydroxyapatite, 
constituting the extracellular matrix. When osteoblasts remain embedded in the bone 
matrix get its final state of differentiation: the osteocyte (Os) (4.). Osteoblast 
eventually become lining cells (5.) or undergo apoptosis (6.). Osteoclasts are 
differentiated from monocyte/macrophage precursors of hematopoietic stem cells 
origin (HSC). M-CSF is secreted by osteoblast and RANKL produced by osteoblast and 
osteocytes promote the survival, proliferation and differentiation of osteoclast 











bone resorption. They create an acidic microenvironment that mobilizes the mineral 
matrix through secreted enzymes, MMPs and cathepsin K, among others (8.). 
 
Fig 3. Interplay between mediators in mesenchymal stem cells (MSCs) differentiation 
to osteoblasts (Ob) or adipocytes (Ad). MSCs are pluripotent progenitor cells that are 
able to differentiate into several cell types, including adipogenic and osteogenic 
lineages depending on the stimulation with distinct growth and differentiation factors. 
The lineage-specific differentiation is a multiple-stage and well-coordinated process 
regulated by master regulators, such as Runx2 and Osterix for osteogenesis (1.); and 
PPARγ and C/EBPβ for adipogenesis (2.). These factors appear reciprocally regulated, 
RUNX2 expression is induced by SIRT1 and WNT and inhibited by PPARγ (1a). 
Additionally, SIRT1 and WNT inhibits adipogenesis: Wnt signaling maintains 
preadipocytes in an undifferentiated state through inhibition of the adipogenic 
transcription factors C/EBP family transcription factors  and PPARγ (2a). Additionally 
adiponectin, secreted by differentiated adipocyte facilitates osteogenesis through 
Wnt/β-catenin pathway (3.).  
 
Fig 4. Altered mechanisms in Gaucher bone pathophysiology. 1. Osteoclastogenesis 
induced by pro-inflamatory cytokines (TNF-α, RANKL, IL-1β) from Gaucher PBMCs, T 
cells, Os and MSC, as well as increased numbers of osteoclast precursors. 2. 
Accumulation of GluCer (2a) induced PPAR-γ which is also overexpresed at genetic 
level in MSC (2b). 3. MSCs are mainly stuck in phase G2 of the cell cycle. 4. Ad 
differentiation: 4a. Lower lipid droplets were observed; 4b. Subexpresion of RUNX2 
and overexpresion of PPARγ. 5. Reduced bone matrix deposition because of altered Ob 
differentiation caused by: 5a. Inhibition of Wnt pathway leads to reduced expresion of 
DVL and high activity of GSK3 leading to phosphorilation of β -catenin, which is 
degraded by the proteasome; 5b. Higher levels of ROS were detected; 5c. Increment in 
lactosylceramide and GluCer; 5d. Subexpresion of RUNX2/Runx2, COLA1/ColA1, 
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